Mar 07, 2024
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Mar 06, 2024
Lipocine to Present at 36th Annual Roth Conference
Feb 06, 2024
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Jan 18, 2024
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
Jan 28, 2021
Lipocine Closes Underwritten Public Offering Of Common Stock
Jan 26, 2021
Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock
Jan 25, 2021
Lipocine Announces Launch Of Public Offering Of Common Stock
Jan 14, 2021
Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
Jan 12, 2021
Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects
Jan 04, 2021
Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference
Dec 30, 2020
Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study
Dec 29, 2020
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics
Dec 08, 2020
Lipocine Announces Deletion of Unauthorized Changes to Company's Website
Dec 04, 2020
Lipocine Provides New Regulatory Update on TLANDO(TM)
Nov 10, 2020
Lipocine Announces Third Quarter 2020 Financial and Operational Results
Nov 05, 2020
Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience(TM)
Sep 21, 2020
Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study
Aug 28, 2020
Lipocine Provides Regulatory Update for TLANDO(TM)
Aug 06, 2020
Lipocine Announces Second Quarter 2020 Financial and Operational Results
Aug 03, 2020
Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results